Big Pharma's forays into Big Data worry some security experts; Teva touts its women-in-management record; Actelion's Uptravi grabs Canadian approval;

@FiercePharma: India's Biocon takes a hit from analysts, but Mazumdar-Shaw upbeat. Story | Follow @FiercePharma

@EricPFierce: #EMA suspends Hubei Hongyuan Pharmaceutical after Czech inspectors find dust-covered plant and equipment. Article | Follow @EricPFierce

@CarlyHFierce: Invokana market share has trended upward post EMPA-REG, $JNJ says. Thank you, $LLY. | Follow @CarlyHFierce

> As a host of top pharma companies--including Novartis ($NVS), Roche ($RHHBY), Novo Nordisk ($NVO) and Sanofi ($SNY)--strike Big Data and cloud-computing deals with tech firms, security experts are worrying about hackers capturing patients' medical information. Report

> Israel-based Teva Pharmaceutical Industries ($TEVA) says almost half of its managers are women, and women occupy 35% of the jobs in it senior executive ranks. Report

> The Swiss-based biotech Actelion won Canadian approval for its new pulmonary arterial hypertension drug Uptravi. Report

> The FDA is scheduled to decide by mid-September whether to approve Amgen's ($AMGN) biosimilar version of AbbVie's ($ABBV) blockbuster Humira. Report

Medical Device News

@FierceMedDev: Theranos flagged by CMS for serious problems at California lab: WSJ. Report | Follow @FierceMedDev

@EmilyWFierce: Big Pharma chalks up victory in Arizona Supreme Court over Rx safety warnings. FiercePharma article | Follow @EmilyWFierce

> J&J hints at 'bold steps' in device deals in 2016, details 5 device collaborations. More

> U.K. startup reels in $45M in JJDC-backed round to boost liquid biopsy ambitions. Article

Biotech News

@FierceBiotech: Amgen's Humira biosimilar nears FDA nod, but legal hurdles remain. Story | Follow @FierceBiotech

@JohnCFierce: So I'll be hanging out at #BIOCEO16 in NYC for a couple of days. Should be fun. | Follow @JohnCFierce

> Codiak piles on more venture cash, amassing $92M for exosome R&D. Story

> With a Duchenne MD patient struggling for life, little Akashi suspends study. More

Pharma Manufacturing News

> Pfizer recalls three lots of top seller Lyrica after production issues. More

> India's Mankind Pharma says it will build a plant in New Jersey. Report

> Inspectors find big issues at API repackager in France. Story

> Teva retrieves amphetamines over impurity concerns. Article

> Sterile injectables manufacturer Sagent said to be shopping itself. More

Pharma Asia News

> Indian firms in a race to buy Nasdaq-listed Sagent, report says. Report

> India and France committed to restart trade talks stalled on GVK row. Story

> Japan's Ono Pharmaceutical gears up sales reps for Opdivo. Item

> China-based VC firm WuXi Healthcare makes coast-to-coast U.S. investments. More

> India's Biocon takes a hit from analysts, but Mazumdar-Shaw upbeat. Article

Drug Delivery News

> Startup Co-D aims to resuscitate failed BMS drug using polymeric micelle drug delivery. More

> UNC team delivers cancer drugs wrapped in exosomes to cut doses. Report

> Combining light-activated and chemical treatments, new nanoparticles are more effective against tumors. Story

> Endangered inhaled insulin player MannKind collaborates with mysterious 'entity' on R&D. Item

> Cancer-focused Ensysce Biosciences adds opioid prodrug to its pipeline via merger. Article

And Finally... Should doctors use drug therapy to put a damper on painful memories? Report

Suggested Articles

An injection that's under FDA priority review as a monthly HIV therapy can suppress the virus even if given every two months, a phase 3 has shown.

Pfizer and Astellas are chasing a new nod for prostate cancer drug Xtandi, and thanks to the FDA, they might not have to wait that long.

Sanofi lost an appeal challenging the ban on its dengue vaccine Dengvaxia in the Philippines, despite an ongoing outbreak there.